SeaStar Medical Holding Co. (NASDAQ:ICU) Short Interest Update

SeaStar Medical Holding Co. (NASDAQ:ICU) was the target of a significant increase in short interest during the month of February. As of February 28th, there was short interest totalling 357,600 shares, an increase of 18.8% from the February 13th total of 300,900 shares. Currently, 4.2% of the company’s stock are short sold. Based on an average daily trading volume, of 421,900 shares, the short-interest ratio is currently 0.8 days.

SeaStar Medical Price Performance

ICU stock traded down $0.02 during trading hours on Thursday, reaching $2.08. The stock had a trading volume of 8,927 shares, compared to its average volume of 246,060. The stock has a market capitalization of $13.46 million, a PE ratio of -0.18 and a beta of -0.97. The stock has a 50-day simple moving average of $1.83 and a 200 day simple moving average of $2.75. SeaStar Medical has a fifty-two week low of $1.50 and a fifty-two week high of $22.00.

Hedge Funds Weigh In On SeaStar Medical

An institutional investor recently raised its position in SeaStar Medical stock. Geode Capital Management LLC lifted its holdings in shares of SeaStar Medical Holding Co. (NASDAQ:ICU) by 14.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 45,430 shares of the company’s stock after acquiring an additional 5,618 shares during the quarter. Geode Capital Management LLC owned approximately 1.02% of SeaStar Medical worth $88,000 as of its most recent SEC filing. 1.69% of the stock is owned by institutional investors and hedge funds.

About SeaStar Medical

SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome.